FORM 10-QSB

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

              [X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                        For Quarter Ended March 31, 2000

                                       OR

              [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)
                     OF THE SECURITIES EXCHANGE ACT OF 1934

                For the transition period from _______ to _______

                         Commission File Number: 0-16335

                          BIO-MEDICAL AUTOMATION, INC.
                          ----------------------------
             (Exact Name of Registrant as Specified in its Charter)

                    COLORADO                      84-0922701
                    --------                      ----------
        State or other jurisdiction of         (I.R.S. Employer
        incorporation or organization          Identification No.)

                 900 Third Avenue, Suite 201, New York, NY 10022
               --------------------------------------------------
               (Address of Principal Executive Office) (Zip Code)

                                 (212) 610-2778
                                 --------------
               (Registrant's telephone number including area code)


            7450 East Jewell Avenue, Suite A, Denver, Colorado 80231
            --------------------------------------------------------
                                (Former Address)


Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the preceding 12 months (or for such shorter period that the registrant was
required to file such reports) and (2) has been subject to such filing
requirements for the past 90 days.
                                                                 Yes [X] No [ ]


The number of shares of the registrant's common stock, $.10 par value,
outstanding as of May 1, 2000 was 643,160 shares.


<PAGE>

                          Bio-Medical Automation, Inc.

                                Table of Contents

                                                                           Page

         Part I   Financial Information ......................................3

         Item 1. Financial Statements ........................................3

         Balance Sheets as of December 31, 1999 and March 31, 2000 ...........3

         Statements of Operations for the
         Three Months Ended March 31, 1999 and 2000 ..........................4

         Statements of Cash Flows for the
         Three Months Ended March 31, 1999 and 2000 ..........................5

         Notes to Financial Statements .......................................6

         Item 2.  Plan of Operation ..........................................6

         Part II   Other Information .........................................8

         Item 5.  Other Information ..........................................8

         Item 6.  Exhibits and Reports on Form 8-K ...........................8

         Signatures ..........................................................8



                                        2
<PAGE>

                         PART I - FINANCIAL INFORMATION

Item 1.           Financial Statements


                          BIO-MEDICAL AUTOMATION, INC.
                                 BALANCE SHEETS

                                                     December 31,    March 31,
                                                         1999          2000
                                                                    (Unaudited)
                                     ASSETS
CURRENT ASSETS
    Cash                                             $   425,211    $   381,814
                                                     -----------    -----------

        Total Current Assets                             425,211        381,814

PATENT COSTS                                              18,724         18,724
                                                     -----------    -----------

                                                     $   443,935    $   400,538
                                                     ===========    ===========


                      LIABILITIES AND STOCKHOLDERS' EQUITY

CURRENT LIABILITIES
    Accounts payable and accrued expenses            $    15,393    $     3,179
                                                     -----------    -----------

        Total Current Liabilities                         15,393          3,179
                                                     -----------    -----------

STOCKHOLDERS' EQUITY
    Preferred Stock, $.10 par value
           Authorized - 1,000,000 shares
           Issued - none                                    --             --
    Common Stock, $.10 par value
           Authorized - 5,000,000 shares
           Issued and outstanding - 643,128 shares        64,313         64,313
    Capital in excess of par value                     1,312,049      1,312,049

    Accumulated (deficit)                               (947,820)      (979,003)
                                                     -----------    -----------


                                                         428,542        397,359
                                                     -----------    -----------

                                                     $   443,935    $   400,538
                                                     ===========    ===========


                 See accompanying notes to financial statements.

                                        3
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                            STATEMENTS OF OPERATIONS

                                                          Three Months Ended
                                                               March 31,
                                                         1999            2000
REVENUES
    Interest income                                   $    --         $   2,855
                                                      ---------       ---------

OPERATING EXPENSES
    General and Administrative                           51,074          34,038
    Research & Development                                2,302            --
    Interest                                              2,500            --
                                                      ---------       ---------

(LOSS) FROM CONTINUING OPERATIONS                       (55,876)        (31,183)
                                                      ---------       ---------

DISCONTINUED OPERATIONS
    Income from discontinued operations                 706,991            --
                                                      ---------       ---------

INCOME BEFORE TAXES                                     651,115         (31,183)
                                                      ---------       ---------


INCOME TAX EXPENSE                                      254,000            --

TAX BENEFIT OF NET OPERATING LOSS
CARRYFORWARDS                                          (254,000)           --
                                                      ---------       ---------

NET INCOME (LOSS)                                     $ 651,115       $ (31,183)
                                                      =========       =========

NET INCOME(LOSS) PER COMMON SHARE -

    Basic and Diluted

    Continuing operations                             $   (0.09)      $   (0.05)
    Discontinued operations                           $    1.10            --
                                                      ---------       ---------

NET INCOME (LOSS) PER COMMON SHARE                    $    1.01       $   (0.05)
                                                      =========       =========

WEIGHTED AVERAGE NUMBER OF
    COMMON SHARES OUTSTANDING -
    Basic and Diluted                                   643,160         643,128
                                                      =========       =========


                 See accompanying notes to financial statements.

                                        4
<PAGE>

                          BIO-MEDICAL AUTOMATION, INC.
                            STATEMENTS OF CASH FLOWS

<TABLE>
<CAPTION>
                                                                        Three Months Ended
                                                                              March 31,
                                                                          1999         2000

<S>                                                                    <C>          <C>
CASH FLOWS FROM OPERATNG ACTIVITIES
    Net income (loss)                                                  $ 651,115    $ (31,183)
    Adjustments to reconcile net income (loss) to net cash
        provided (used) by operating activities

    Changes in assets and liabilities
        (Increase) in accounts receivable                                 (8,150)        --
        Increase (decrease) in accounts payable and accred  expenses       3,981      (12,215)

    Discontinued operations:
        Operating cash provided                                          115,905         --
        Depreciation and amortization                                      7,929         --
                                                                       ---------    ---------

    Net Cash Provided (Used) by Operating Activities                     770,780      (43,398)
                                                                       ---------    ---------

CASH FLOWS FROM INVESTING ACTIVITIES
    Payments for patent costs                                             (3,709)        --
                                                                       ---------    ---------

    Net Cash (Used) in Investing Activities                               (3,709)        --
                                                                       ---------    ---------

CASH FLOWS FROM FINANCING ACTIVITIES
    Proceeds from officer loan                                            40,000         --
    Payments on officer loan                                             (75,000)        --
    Cash repayments by continuing operations                            (130,000)        --
    Cash repayment by discontinued operations                             (7,133)        --
                                                                       ---------    ---------

    Net Cash (Used) by Financing Activities                             (172,133)        --
                                                                       ---------    ---------

NET INCREASE (DECREASE) IN CASH                                          594,938      (43,398)

CASH, BEGINNING OF PERIODS                                                 8,150      425,212
                                                                       ---------    ---------

CASH, END OF PERIODS                                                   $ 603,088    $ 381,814
                                                                       =========    =========
</TABLE>

                 See accompanying notes to financial statements.

                                        5
<PAGE>

                          NOTES TO FINANCIAL STATEMENTS
                   Three Months Ended March 31, 2000 and 1999
                                   (UNAUDITED)

         The unaudited financial statements included herein were prepared from
the records of the Company in accordance with Generally Accepted Accounting
Principles and reflect all adjustments which are, in the opinion of management,
necessary to provide a fair statement of the results of operations and financial
position for the interim periods. Such financial statements generally conform to
the presentation reflected in the Company's Form 10-KSB filed with the
Securities and Exchange Commission for the year ended December 31, 1999. The
current interim period reported herein should be read in conjunction with the
Company's Form 10-KSB subject to independent audit at the end of the year.

         The results of operations for the three months ended March 31, 2000 are
not necessarily indicative of the results that may be expected for the year
ending December 31, 2000.


Item 2.        PLAN OF OPERATIONS

         The following discussion and analysis provides information which the
Company's management believes to be relevant to an assessment and understanding
of the Company's results of operations and financial condition. This discussion
should be read together with the Company's financial statements and the notes to
financial statements, which are included in this report, as well as the
Company's Form 10-KSB for the year ended December 31, 1999.

         On March 9, 1999, the Company completed the sale of substantially all
of its assets to JOT Automation, Inc. (the "JOT Transaction"). As a result of
the completion of the JOT Transaction, the Company's historical business, the
depaneling and routing business, is considered to be a "discontinued operation"
and, consequently, provides no benefit to persons seeking to understand the
Company's financial condition or results of operations.

         As disclosed in prior filings, following the JOT Transaction the
Company devoted its efforts to the development of the prototype micro robotic
device. The Company has not completed the development of the technology
necessary for the completion of the prototype device. The Company has been
unable to accomplish this goal because of the unavailability of the device's
designer, David W. Orthman. It is unlikely that the Company will ever complete
the development of micro robotic device. The Company has never derived any
revenues from the micro robotic device and there can be no assurance that the
Company will ever derive any revenues from this technology.

         On March 25, 2000, there occurred a change in control of Company. This
event was disclosed on a current report on Form 8-K, dated April 5, 2000, which
is incorporated herein by reference. Following the change in control the Company
relocated its offices to 900 Third Avenue, Suite 201, New York, New York 10022.
The Company currently utilizes a portion of the premises occupied by Steven N.
Bronson as its corporate office, at no charge to the Company.

                                        6
<PAGE>

Results of Operations
---------------------

         For the three months ended March 31, 2000, the Company has not earned
any revenues, except for interest income of $2,855. For the same period the
Company incurred general and administrative expenses of $34,038 resulting in a
net loss from operations equal to $31,183. General and administrative
expenditures were and have been directed to maintaining the Company's status as
a public company, including (without limitation) filing reports with the
Securities and Exchange Commission.

Liquidity and Capital Resources
-------------------------------

         During three months ended March 31, 2000, the Company satisfied its
working capital needs from cash on hand at the beginning of the quarter and cash
generated from interest income during the quarter. As of March 31, 2000, the
Company had on hand cash in the amount of $381,814.

         The Company had anticipated spending this working capital to complete
the development of the prototype device and related technology, as described
above. However, the Company has been unable to accomplish this goal and there
can be no assurances that the Company will be able to complete the development
of the prototype device and related technology or derive any revenues therefrom.
Unless the Company is able to generate revenues from the prototype device and
related technology, or unless the Company is able to acquire a new line of
business on commercially reasonable terms, the Company's liquidity will continue
to be reduced over time.

         Alternatively, the Company's future financial condition will be subject
to its ability to arrange for a merger, acquisition or a business combination
with an operating business on favorable terms that will result in profitability.
There can be no assurance that the Company will be able to do so or, if it is
able to do so, that the transaction will be on favorable terms not resulting in
an unreasonable amount of dilution to the Company's existing shareholders.

         The Company may need additional funds in order to effectuate a merger,
acquisition or other arrangement by and between the Company and a viable
operating entity, although there is no assurance that the Company will be able
to obtain such additional funds, if needed. Even if the Company is able to
obtain additional funds there is no assurance that the Company will be able to
effectuate a merger, acquisition or other arrangement by and between the Company
and a viable operating entity.

         Except for historical information contained herein, the statements in
this report are forward-looking statements that are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties,
which may cause the Company's actual results in future periods to differ
materially, from forecasted results. These and other risks are described
elsewhere herein and in the Company's other filings with the Securities and
Exchange Commission, namely the Company's Form 10-KSB for the year ended
December 31, 1999.

                                        7
<PAGE>

                                            PART II - OTHER INFORMATION

Item 5.        Other Information

               On March 25, 2000, Steven N. Bronson acquired control of the
               Company. Simultaneously, with the change of control all directors
               and officers of the Company resigned. Steven N. Bronson, Leonard
               Hagan and Kenneth S. Schwartz were appointed to the Board of
               Directors of the Company and Steven N. Bronson became the sole
               officer of the Company. The Company issued a disclosure statement
               pursuant to Rule 14(f)-1 to the shareholders reporting this event
               and filed a current report on Form 8-K, dated April 5, 2000.

Item 6.        Exhibits and Reports on Form 8-K

               a)       Exhibits

                        Exhibit 27 -  Financial Data Schedule

               b)       The Company filed a current report on Form 8-K
                        reporting a change in control of the Company as of
                        March 25, 2000.


                                   SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this Report to be signed on its behalf by the
undersigned thereunto duly authorized.


                                  BIO-MEDICAL AUTOMATION, INC.


                                  By: /s/ Steven N. Bronson
                                      ---------------------------
                                      Steven N. Bronson, President
                                      (Principle Executive Officer),
                                      as Registrant's duly authorized officer


Dated:  May 22, 2000



                                        8